List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1558507/publications.pdf Version: 2024-02-01

		87843	54882
141	7,413	38	84
papers	citations	h-index	g-index
143	143	143	7804
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Perioperative Management of Antithrombotic Therapy. Chest, 2012, 141, e326S-e350S.	0.4	1,461
2	Antithrombotic Therapy for Atrial Fibrillation. Chest, 2012, 141, e531S-e575S.	0.4	891
3	The Effect of Warfarin and Intensity of Anticoagulation on Outcome of Intracerebral Hemorrhage. Archives of Internal Medicine, 2004, 164, 880.	4.3	544
4	Can Patients Be Anticoagulated After Intracerebral Hemorrhage?. Stroke, 2003, 34, 1710-1716.	1.0	303
5	Cost-Effectiveness of Using Pharmacogenetic Information in Warfarin Dosing for Patients With Nonvalvular Atrial Fibrillation. Annals of Internal Medicine, 2009, 150, 73.	2.0	259
6	Moving the Tipping Point. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 14-21.	0.9	234
7	Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines. Chest, 2012, 141, 53S-70S.	0.4	213
8	Foot Infections in Diabetic Patients. JAMA - Journal of the American Medical Association, 1995, 273, 712.	3.8	183
9	Effect of Macrolides as Part of Initial Empiric Therapy on Length of Stay in Patients Hospitalized With Community-Acquired Pneumonia. Archives of Internal Medicine, 1999, 159, 2576.	4.3	143
10	Statin Use Following Intracerebral Hemorrhage. Archives of Neurology, 2011, 68, 573-9.	4.9	110
11	Grades of Recommendation for Antithrombotic Agents. Chest, 1998, 114, 441S-444S.	0.4	104
12	Impact of health literacy on outcomes and effectiveness of an educational intervention in patients with chronic diseases. Patient Education and Counseling, 2012, 87, 143-151.	1.0	103
13	Screening for the Risk for Bleeding or Thrombosis. Annals of Internal Medicine, 2003, 138, W-15W-24.	2.0	94
14	Antithrombotic Therapy in Valvular Heart Disease. Chest, 1998, 114, 590S-601S.	0.4	85
15	Cost-effectiveness of Screening for Chronic Hepatitis C Infection in the United States. Clinical Infectious Diseases, 2013, 56, 1382-1393.	2.9	80
16	The Cost-effectiveness of Screening for Chronic Hepatitis B Infection in the United States. Clinical Infectious Diseases, 2011, 52, 1294-1306.	2.9	74
17	Cost-effectiveness of Interferon Gamma Release Assays vs Tuberculin Skin Tests in Health Care Workers. Archives of Internal Medicine, 2009, 169, 179.	4.3	73
18	Effect of Laboratory Variation in the Prothrombin-Time Ratio on the Results of Oral Anticoagulant Therapy. New England Journal of Medicine, 1993, 329, 696-702.	13.9	71

#	Article	IF	CITATIONS
19	Cost Effectiveness of Universal Screening for Hepatitis CÂVirus Infection in the Era of Direct-Acting, Pangenotypic Treatment Regimens. Clinical Gastroenterology and Hepatology, 2019, 17, 930-939.e9.	2.4	70
20	Subthalamic nucleusâ€deep brain stimulation for early motor complications in Parkinson's disease—the EARLYSTIM trial: Early is not always better. Movement Disorders, 2014, 29, 1751-1756.	2.2	68
21	Predictors of Warfarin Use Among Ohio Medicaid Patients With New-Onset Nonvalvular Atrial Fibrillation. Archives of Internal Medicine, 2003, 163, 1705.	4.3	66
22	Cost-effectiveness of Therapies for Patients With Nonvalvular Atrial Fibrillation. Archives of Internal Medicine, 1998, 158, 1669.	4.3	65
23	Anticoagulation for Noncardiac Procedures in Patients With Prosthetic Heart Valves. JAMA - Journal of the American Medical Association, 1990, 263, 1513.	3.8	61
24	Management and prevention of thromboembolic events in patients with cancer-related hypercoagulable states. Journal of General Internal Medicine, 1993, 8, 476-486.	1.3	61
25	Cost Effectiveness of Oral as Compared with Intravenous Antibiotic Therapy for Patients with Early Lyme Disease or Lyme Arthritis. New England Journal of Medicine, 1997, 337, 357-364.	13.9	59
26	Making Decisions About Antithrombotic Therapy in Heart Disease: Decision Analytic and Costeffectiveness Issues. Chest, 1998, 114, 699S-714S.	0.4	56
27	Individualizing Therapy to Prevent Long-term Consequences of Estrogen Deficiency in Postmenopausal Women. Archives of Internal Medicine, 1999, 159, 1458.	4.3	56
28	Antithrombotic Therapy in Valvular Heart Disease. Chest, 2001, 119, 207S-219S.	0.4	56
29	Impact of Bariatric Surgery on Life Expectancy in Severely Obese Patients With Diabetes. Annals of Surgery, 2015, 261, 914-919.	2.1	51
30	Health values of adolescents with cystic fibrosis. Journal of Pediatrics, 2003, 142, 133-140.	0.9	48
31	Warfarin for Dilated Cardiomyopathy. Medical Decision Making, 1989, 9, 162-169.	1.2	47
32	Radioiodine or Surgery for Toxic Thyroid Adenoma: Dissecting an Important Decision. A Cost-Effectiveness Analysis. Thyroid, 2004, 14, 933-945.	2.4	47
33	Direct Angioplasty for Acute Myocardial Infarction. Annals of Internal Medicine, 1992, 117, 667-676.	2.0	45
34	The Potential of Shared Decision Making to Reduce Health Disparities. Journal of Law, Medicine and Ethics, 2011, 39, 30-33.	0.4	44
35	Chest Computed Tomographic Image Screening for Cystic Lung Diseases in Patients with Spontaneous Pneumothorax Is Cost Effective. Annals of the American Thoracic Society, 2017, 14, 17-25.	1.5	44
36	Psychosocial risk factors for adverse outcomes in patients with nonvalvular atrial fibrillation receiving warfarin. Journal of General Internal Medicine, 2005, 20, 1114-1119.	1.3	43

#	Article	IF	CITATIONS
37	Cost-effectiveness analysis of ED decision making in patients with non–high-risk heart failure. American Journal of Emergency Medicine, 2009, 27, 293-302.	0.7	43
38	Impact of an Atrial Fibrillation Decision Support Tool on thromboprophylaxis for atrial fibrillation. American Heart Journal, 2016, 176, 17-27.	1.2	42
39	Early versus delayed bilateral subthalamic deep brain stimulation for parkinson's disease: A decision analysis. Movement Disorders, 2010, 25, 1456-1463.	2.2	40
40	Patient-Specific Decision-Making for Warfarin Therapy in Nonvalvular Atrial Fibrillation. Stroke, 2008, 39, 3308-3315.	1.0	39
41	Thiopurine S-Methyltranferase Testing in Idiopathic Pulmonary Fibrosis: A Pharmacogenetic Cost-Effectiveness Analysis. Lung, 2010, 188, 125-132.	1.4	39
42	Net Clinical Benefit of Oral Anticoagulation Among Older Adults With Atrial Fibrillation. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e006212.	0.9	37
43	Decision Analytic and Cost-Effectiveness Issues Concerning Anticoagulant Prophylaxis in Heart Disease. Chest, 1992, 102, 538S-549S.	0.4	35
44	Prophylactic use of the intro-aortic balloon pump in high-risk cardiac patients undergoing noncardiac surgery: A decision analytic view. American Journal of Medicine, 1992, 92, 665-678.	0.6	35
45	Costâ€effectiveness of intravenous acetaminophen for pediatric tonsillectomy. Paediatric Anaesthesia, 2014, 24, 467-475.	0.6	35
46	Cost-Effectiveness of Total Pancreatectomy and Islet Cell Autotransplantation for the Treatment of Minimal Change Chronic Pancreatitis. Journal of Gastrointestinal Surgery, 2015, 19, 46-55.	0.9	34
47	Developing an Atrial Fibrillation Guideline Support Tool (AFGuST) for shared decision making. Current Medical Research and Opinion, 2015, 31, 603-614.	0.9	32
48	Combined aspirin and anticoagulant therapy in patients with atrial fibrillation. Journal of Thrombosis and Thrombolysis, 2017, 43, 7-17.	1.0	31
49	Cost-effectiveness of prophylactic low molecular weight heparin in pregnant women with a prior history of venous thromboembolism. American Journal of Medicine, 2005, 118, 503-514.	0.6	29
50	Prehospital Triage of Acute Ischemic Stroke Patients to an Intravenous tPA-Ready versus Endovascular-Ready Hospital: A Decision Analysis. Prehospital Emergency Care, 2018, 22, 722-733.	1.0	29
51	Underuse of Controller Medications Among Children With Persistent Asthma in the Ohio Medicaid Population: Evolving Differences With New Medications. Academic Pediatrics, 2005, 5, 83-89.	1.7	28
52	Decision Modeling to Estimate the Impact of Gastric Bypass Surgery on Life Expectancy for the Treatment of Morbid Obesity. Archives of Surgery, 2010, 145, 57.	2.3	28
53	Outcomes of Hemodialysis Patients in a Long-term Care Hospital Setting: A Single-Center Study. American Journal of Kidney Diseases, 2010, 55, 300-306.	2.1	28
54	Antithrombotic Therapy in Valvular Heart Disease. Chest, 1992, 102, 434S-444S.	0.4	27

#	Article	IF	CITATIONS
55	Application of a Decision Support Tool for Anticoagulation in Patients with Non-valvular Atrial Fibrillation. Journal of General Internal Medicine, 2008, 23, 411-417.	1.3	27
56	Oral Cyclophosphamide for Active Scleroderma Lung Disease: A Decision Analysis. Medical Decision Making, 2008, 28, 926-937.	1.2	27
57	Integrating Real-Time Clinical Information to Provide Estimates of Net Clinical Benefit of Antithrombotic Therapy for Patients With Atrial Fibrillation. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 680-686.	0.9	27
58	Time to Angiographic Reperfusion in Acute Ischemic Stroke. Stroke, 2014, 45, 3625-3630.	1.0	26
59	Cost-effectiveness of Using Kidneys From HCV-Viremic Donors for Transplantation Into HCV-Uninfected Recipients. American Journal of Kidney Diseases, 2020, 75, 857-867.	2.1	26
60	Making Decisions About Antithrombotic Therapy in Heart Disease. Chest, 1995, 108, 457S-470S.	0.4	25
61	Costâ€effectiveness of intravenous acetaminophen and ketorolac in adolescents undergoing idiopathic scoliosis surgery. Paediatric Anaesthesia, 2018, 28, 237-248.	0.6	24
62	Women's Values and Preferences for Thromboprophylaxis during Pregnancy: A Comparison of Direct-choice and Decision Analysis using Patient Specific Utilities. Thrombosis Research, 2015, 136, 341-347.	0.8	23
63	Women's values and preferences and health state valuations for thromboprophylaxis during pregnancy: A cross-sectional interview study. Thrombosis Research, 2016, 140, 22-29.	0.8	23
64	Transplanting Hepatitis C Virus–Infected Versus Uninfected Kidneys Into Hepatitis C Virus–Infected Recipients. Annals of Internal Medicine, 2018, 169, 214.	2.0	23
65	Prophylactic pasireotide administration following pancreatic resection reduces cost while improving outcomes. Journal of Surgical Oncology, 2016, 113, 784-788.	0.8	22
66	A Scoping Review of Health Information Technology in Clinician Burnout. Applied Clinical Informatics, 2021, 12, 597-620.	0.8	22
67	Automated Critiquing of Medical Decision Trees. Medical Decision Making, 1989, 9, 272-284.	1.2	21
68	Antithrombotic Therapy in Valvular Heart Disease. Chest, 1995, 108, 360S-370S.	0.4	21
69	Sugammadex versus neostigmine for routine reversal of rocuronium block in adult patients: A cost analysis. Journal of Clinical Anesthesia, 2020, 67, 110027.	0.7	20
70	Using an Atrial Fibrillation Decision Support Tool for Thromboprophylaxis in Atrial Fibrillation: Effect of Sex and Age. Journal of the American Geriatrics Society, 2016, 64, 1054-1060.	1.3	19
71	Shared decision-making tool for thromboprophylaxis in atrial fibrillation – A feasibility study. American Heart Journal, 2018, 199, 13-21.	1.2	19
72	Effect of Variation in Published Stroke Rates on the Net Clinical Benefit of Anticoagulation for Atrial Fibrillation. Annals of Internal Medicine, 2018, 169, 517.	2.0	19

#	Article	IF	CITATIONS
73	Cost-Effectiveness of Latent Tuberculosis Screening Before Steroid Therapy for Idiopathic Nephrotic Syndrome in Children. American Journal of Kidney Diseases, 2013, 61, 22-32.	2.1	17
74	Racial Disparities in the Filling of Warfarin Prescriptions for Nonvalvular Atrial Fibrillation. American Journal of the Medical Sciences, 2007, 333, 67-73.	0.4	16
75	Costâ€effectiveness of Telemetry for Hospitalized Patients With Lowâ€risk Chest Pain. Academic Emergency Medicine, 2011, 18, 279-286.	0.8	15
76	Pancreas fistula risk prediction: implications for hospital costs and payments. Hpb, 2017, 19, 140-146.	0.1	15
77	Testing for Factor V Leiden in Patients with Pulmonary or Venous Thromboembolism: A Cost-Effectiveness Analysis. Medical Decision Making, 2002, 22, 108-124.	1.2	14
78	Inaccuracies in Estimates of Life Expectancies of Patients with Bronchial Cancer in Clinical Decision Making. Medical Decision Making, 1993, 13, 237-244.	1.2	12
79	Cost effectiveness of recombinant factor VIIa for treatment of intracerebral hemorrhage. BMC Neurology, 2008, 8, 17.	0.8	12
80	Should We Test for CYP2C9 Before Initiating Anticoagulant Therapy in Patients with Atrial Fibrillation?. Journal of General Internal Medicine, 2009, 24, 543-549.	1.3	11
81	Eaton-Lambert Syndrome and Small Cell Lung Cancer. Medical Decision Making, 1986, 6, 174-186.	1.2	10
82	A Counterpoint to the Analytic Hierarchy Process. Medical Decision Making, 1989, 9, 57-58.	1.2	10
83	Determinants of Hospitalist Efficiency. Medical Care Research and Review, 2009, 66, 682-702.	1.0	10
84	Data and meta-analysis for choosing sugammadex or neostigmine for routine reversal of rocuronium block in adult patients. Data in Brief, 2020, 32, 106241.	0.5	10
85	Patient-Centered Decision Making: A View of the Past and a Look toward the Future. Medical Decision Making, 2001, 21, 241-247.	1.2	10
86	The Timing of Radical Cystectomy after Recent Myocardial Infarction. Medical Decision Making, 1987, 7, 52-66.	1.2	9
87	Longitudinal Analysis of Genitourinary and Bowel Symptoms in Prostate Cancer Patients Following Brachytherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 1-10.	0.6	9
88	Usability of an Atrial Fibrillation Anticoagulation Decision-Support Tool. Journal of Primary Care and Community Health, 2011, 2, 100-106.	1.0	9
89	Evaluating patient values and preferences for thromboprophylaxis decision making during pregnancy: a study protocol. BMC Pregnancy and Childbirth, 2012, 12, 40.	0.9	9
90	Predictors of bariatric surgery among an interested population. Surgery for Obesity and Related Diseases, 2014, 10, 547-552.	1.0	9

#	Article	IF	CITATIONS
91	Cost-effectiveness of cervical spine clearance interventions with litigation and long-term-care implications in obtunded adult patients following blunt injury. Journal of Trauma and Acute Care Surgery, 2016, 81, 897-904.	1.1	9
92	Atrial fibrillation decision support tool: Population perspective. American Heart Journal, 2017, 194, 49-60.	1.2	9
93	Decision-making about the use of non-vitamin K oral anticoagulant therapies for patients with atrial fibrillation. Journal of Thrombosis and Thrombolysis, 2016, 41, 234-240.	1.0	8
94	Cervical spine evaluation in pediatric trauma: A cost-effectiveness analysis. American Journal of Emergency Medicine, 2020, 38, 2347-2355.	0.7	8
95	HLA-Matched Donor Registries for Bone Marrow Transplants: A Decision Analysis. International Journal of Technology Assessment in Health Care, 1986, 2, 507-531.	0.2	7
96	Understanding preferences for disclosure of individual biomarker results among participants in a longitudinal birth cohort. Journal of Medical Ethics, 2010, 36, 736-740.	1.0	7
97	Valuation of scleroderma and psoriatic arthritis health states by the general public. Health and Quality of Life Outcomes, 2010, 8, 112.	1.0	7
98	Cost-effectiveness of Sexually Transmitted Infection Screening for Adolescents and Young Adults in the Pediatric Emergency Department. JAMA Pediatrics, 2021, 175, 81.	3.3	7
99	Biologic Complexity in Mathematical Modeling. Medical Decision Making, 1989, 9, 38-39.	1.2	6
100	A Decision Analytic View of Anticoagulant Prophylaxis for Thromboembolism in Heart Disease. Chest, 1989, 95, 161S-169S.	0.4	6
101	Cost-Effectiveness Analysis of an Adherence-Promotion Intervention for Children With Leukemia: A Markov Model-Based Simulation. Journal of Pediatric Psychology, 2018, 43, 758-768.	1.1	6
102	Cost-Effectiveness of Utilization of Hepatitis B Virus-Positive Liver Donors for HBV-Negative Transplant Recipients. Journal of Gastrointestinal Surgery, 2021, 25, 1760-1769.	0.9	6
103	Automated Tool for Health Utility Assessments: The Gambler II. MDM Policy and Practice, 2020, 5, 238146832091430.	0.5	6
104	Aortic Aneurysm in a 74-year-old Man with Coronary Disease and Obstructive Lung Disease. Medical Decision Making, 1989, 9, 285-299.	1.2	5
105	Use of Regression Modeling to Simulate Patient-Specific Decision Analysis for Patients with Nonvalvular Atrial Fibrillation. Medical Decision Making, 2003, 23, 361-368.	1.2	5
106	"Bridging On the River Kwai― The Perioperative Management of Anticoagulation Therapy. Medical Decision Making, 2005, 25, 370-373.	1.2	5
107	Anticoagulation in pulmonary arterial hypertension: a decision analysis. Pulmonary Circulation, 2019, 9, 1-12.	0.8	5
108	A Decision Analytic View of Anticoagulant Prophylaxis for Thromboembolism in Heart Disease. Chest, 1986, 89, 995-1065.	0.4	4

#	Article	IF	CITATIONS
109	PREDICTORS OF LENGTH OF HOSPITAL STAY IN COMMUNITY-ACQUIRED PNEUMONIA. Infectious Diseases in Clinical Practice, 2002, 11, 46-51.	0.1	4
110	Interruption of Warfarin Anticoagulation for Dental Surgery: Response. Chest, 2013, 144, 1424-1426.	0.4	4
111	Shared Decision-Making Tool for Self-Management of Home Therapies for Patients With Cystic Fibrosis. MDM Policy and Practice, 2017, 2, 238146831771562.	0.5	4
112	Decision Analysis in SHared decision making for Thromboprophylaxis during Pregnancy (DASH-TOP): a sequential explanatory mixed methods pilot study protocol. BMJ Open, 2021, 11, e046021.	0.8	4
113	More work needed on decision analysis for shared decision-making: A scoping review. Journal of Clinical Epidemiology, 2022, 141, 106-120.	2.4	4
114	Design and rationale for the supermarket and web-based intervention targeting nutrition (SuperWIN) for cardiovascular risk reduction trial. American Heart Journal, 2022, 248, 21-34.	1.2	4
115	Let's decide who's playing, doctor!. Journal of Chronic Diseases, 1986, 39, 679-680.	1.3	3
116	Finding What You Seek: Analyzing Therapies for Nonvalvular Atrial Fibrillation. Annals of Internal Medicine, 1999, 130, 690.	2.0	3
117	Presidential Reflections on the 25th Anniversary of the Society for Medical Decision Making. Medical Decision Making, 2004, 24, 408-420.	1.2	3
118	Ischemic Stroke and Bleeding. Stroke, 2020, 51, 808-814.	1.0	3
119	A Cost-effectiveness Analysis of Adherence Promotion Strategies to Improve Rejection Rates in Adolescent Kidney Transplant Recipients. American Journal of Kidney Diseases, 2022, 80, 330-340.	2.1	3
120	Strategies for Individualizing Patient Decisions About Hormone Therapy. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1799-1802.	1.8	2
121	A Randomized Study of Scleroderma Health State Values: A Picture Is Worth a Thousand Words, and Quite a Few Utilities. Medical Decision Making, 2009, 29, 7-14.	1.2	2
122	The Use of z Scores in Probabilistic Sensitivity Analyses. Medical Decision Making, 2014, 34, 403-406.	1.2	2
123	Prescribing of anticoagulation for atrial fibrillation in primary care. Journal of Thrombosis and Thrombolysis, 2022, 54, 616-624.	1.0	2
124	Patient-specific decision modeling to guide the use of drotrecogin α (activated) in patients with severe sepsis. Journal of Critical Care, 2008, 23, 484-492.	1.0	1
125	How Much Should We Pay to Minimize Pancreatic Leak? The Cost-effectiveness of Pasireotide in Pancreatic Resection. Annals of Surgery, 2016, Publish Ahead of Print, .	2.1	1
126	Restarting Anticoagulants after a Gastrointestinal Hemorrhage�Between Rockall and a Hard Place. Journal of Hospital Medicine, 2019, 14, 448.	0.7	1

#	Article	IF	CITATIONS
127	Incorporating Patients' Values and Preferences Into Decision Making About Transplantation of HCV-NaÃīve Recipients With Kidneys From HCV-Viremic Donors: A Feasibility Study. MDM Policy and Practice, 2021, 6, 238146832110565.	0.5	1
128	Electronic health record-embedded decision support to reduce stroke risk in patients with atrial fibrillation – Study protocol. American Heart Journal, 2022, 247, 42-54.	1.2	1
129	Racial and sex differences in optimizing anticoagulation therapy for patients with atrial fibrillation. American Heart Journal Plus, 2022, 18, 100170.	0.3	1
130	Clinical Impact of Inaccuracies in Anticoagulation Monitoring. Archives of Internal Medicine, 1995, 155, 115.	4.3	0
131	Additional Factors That Could Improve Cost-Effectiveness of Pharmacogenetic-Guided Dosing in Warfarin Therapy. Annals of Internal Medicine, 2009, 151, 71.	2.0	0
132	Cost-effectiveness of Tuberculosis Screening in Health Care Workers Is Not Robust—Reply. Archives of Internal Medicine, 2009, 169, 1336.	4.3	0
133	Testing for CYP2C9 Before Anticoagulant Therapy. Journal of General Internal Medicine, 2009, 24, 993-993.	1.3	0
134	Reply: Early versus delayed bilateral subthalamic deep brain stimulation for Parkinson's disease: Need for longâ€ŧerm clinical trials. Movement Disorders, 2011, 26, 1371-1371.	2.2	0
135	Transplanting Hepatitis C Virus–Infected or Uninfected Kidneys Into Hepatitis C Virus–Infected Recipients. Annals of Internal Medicine, 2018, 169, 898.	2.0	0
136	Take Your Best Shot: Which SARS-CoV-2 Vaccine Should I Get?. MDM Policy and Practice, 2021, 6, 238146832110312.	0.5	0
137	Predicting Adverse Events Among Patients With COPD Exacerbations in the Emergency Department. Respiratory Care, 2022, 67, 56-65.	0.8	0
138	Making Decisions about Thromboprophylaxis in Pregnancy: Women's Values and Preferences. Blood, 2014, 124, 4833-4833.	0.6	0
139	A Markov Model of Phase I Clinical Trials before or after Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma. Blood, 2015, 126, 3170-3170.	0.6	0
140	Low Molecular Weight Heparin Vs Direct Oral Anticoagulants (Apixaban, Edoxaban and Rivaroxaban) for the Treatment of Cancer Associated Thrombosis: A Cost- Effective Analysis. Blood, 2019, 134, 328-328.	0.6	0
141	Primary PTCA reduces short-term mortality but PTCA after thrombolysis shows no benefit in acute MI. ACP Journal Club, 1995, 123, 8.	0.1	0